|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1.
|
8553070 |
1996 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We recently identified a novel tumor-suppressor gene, DPC4, at chromosome 18q21.1 and found that both alleles of DPC4 were inactivated in nearly one-half of the pancreatic carcinomas.
|
8653691 |
1996 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
DPC4 was identified in a consensus area of homozygous deletion in pancreatic carcinomas, and it is biallelically inactivated in approximately 50% of sporadic pancreatic carcinomas.
|
9098646 |
1997 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Together with the deletion of DPC4 from pancreas carcinomas these results suggest a role for DPC4 as a tumour suppressor.
|
9150356 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We tested for DPC4 gene mutations and allelic status at 18q21 in 30 primary gastric carcinomas and 5 gastric carcinoma cell lines.
|
9197522 |
1997 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Three candidate tumor suppressor genes, DCC (deleted in colorectal carcinomas), DPC4 (deleted in pancreatic carcinomas, locus 4), and MADR2/JV18-1 (MAD-related gene 2), have been cloned and identified from this chromosome region.
|
9288786 |
1997 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
One case of apparent biallelic inactivation of Smad4 was found in our study of 35 gastric carcinomas.
|
9331080 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Smad2 and Smad4/DPC4, other members of the Smad family, are possibly tumor suppressor genes because alterations of these genes occurred in various carcinomas.
|
9464505 |
1998 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Five of 32 (16%) primary biliary tract carcinomas had point mutations in the DPC4 sequence.
|
9515793 |
1998 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Smad4 is a tumor suppressor that is inactivated in about 50% of pancreatic carcinomas.
|
9665198 |
1998 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic alterations of DPC4, which encodes a DNA binding protein that is a downstream component of the pathway, most frequently occur in pancreatic and biliary carcinomas.
|
9850059 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Losses of 15q and 18q material are frequent in pancreatic carcinomas, and in order to map the extent of 15q and 18q deletions and to investigate further the involvement of SMAD4 and the possible function of SMAD2 and SMAD3 as tumor suppressor genes in pancreatic carcinoma, we performed loss of heterozygosity studies as well as mutation and expression analyses of SMAD4, SMAD2, and SMAD3 in 13 low-passage cell lines from 12 pancreatic carcinoma patients.
|
9892110 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.
|
10327057 |
1999 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss of the other allele was observed in 19 of 20 (95%) invasive and metastasized carcinomas with Smad4 mutations.
|
10340381 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We recently identified DPC4/Smad4 as a candidate tumor suppressor gene mutated or lost in one half of pancreatic carcinomas and in a subset of colon and biliary tract carcinomas.
|
10340387 |
1999 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The DPC4 gene (also known as SMAD4) was located in this region, and was found to be inactivated by intragenic mutations in another 20% of pancreatic carcinomas.
|
10436786 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The sensitivity and specificity of immunohistochemical labeling for Dpc4 in other periampullary carcinomas has yet to be determined.
|
10623651 |
2000 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Bi-allelic inactivation of the MADH4/DPC4/SMAD4 gene at 18q21.1 is seen in about half of pancreatic carcinomas with 18q LOH.
|
10719364 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In three cases, the pattern of Dpc4 expression in the PanIN-3 lesions did not match the pattern of expression in the associated infiltrating carcinomas, indicating that these high-grade lesions did not simply represent infiltrating carcinoma growing along benign ducts.
|
10766191 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The strong and almost universal expression of Dpc4 in IPMNs contrasts sharply with the loss of Dpc4 expression seen in approximately 30% of in situ adenocarcinomas of the pancreas (so-called pancreatic intraepithelial neoplasms, grade 3; P: < 0.001) and in 55% of pancreatic duct carcinomas (P: < 0.0001).
|
10980115 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On the contrary, Smad-4 gene levels were elevated in carcinomas when compared to that of adenomas.
|
11196469 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, mutational analysis of K-ras codon 12, APC, and p53 and immunohistochemistry for Smad4 expression were performed on all carcinomas.
|
11215281 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results demonstrate that abnormalities in DPC4 and p53 gene expression are frequent in distal common bile duct carcinomas, just as they are in pancreatic ductal adenocarcinoma, suggesting that these two tumor types might share a similar molecular pathogenesis.
|
11283934 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Abnormal p53 and Dpc4 protein expression was only rarely identified in PanIN-2 lesions, but occurred frequently in PanIN-3 lesions and invasive carcinomas.
|
11337365 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
DNA sequencing and immunohistochemical staining for Smad4/DPC4, which often is homozygously mutated in pancreatic and colon carcinomas, revealed no aberrations.
|
11351300 |
2001 |